You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 7, 2024

Details for Patent: RE48286

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE48286 protect, and when does it expire?

Patent RE48286 protects OCALIVA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: RE48286

Title:	Steroids as agonists for FXR
Abstract:	The invention relates to compounds of formula (I): ##STR00001## wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
Inventor(s):	Pellicciari; Roberto (Perugia, IT)
Assignee:	Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:	16/448,503
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;

Drugs Protected by US Patent RE48286

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE48286

PCT Information
PCT Filed	February 21, 2002	PCT Application Number:	PCT/EP02/01832
PCT Publication Date:	September 19, 2002	PCT Publication Number:	WO02/072598

International Family Members for US Patent RE48286

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	303399	⤷ Try a Trial
Australia	2002308295	⤷ Try a Trial
Canada	2440680	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.